Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast hereCarlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) ...
The therapy in question is HPP737, a phosphodiesterase type 4 (PDE4) inhibitor that vTv has taken into phase 1 development to treat psoriasis. Newsoara originally secured the rights for the drug in ...
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to ...
Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission ...
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ...
The results, published in JCI Insight, suggest that the drug apremilast—a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation—could be repurposed as a ...
the terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PALI-2108 across FSCD ...
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results